In 2020 series, we summarized the major clinical research advances in gynecologic oncology with providing representative figures of the most influential study for 1 of each 3 gynecologic cancers: cervix, ovary, and uterine corpus. Review for cervical cancer covered targeted agents and immune checkpoint inhibitors, adjuvant radiation therapy or concurrent/sequential chemoradiation therapy after radical hysterectomy in early cervical cancer, radical surgery in early cervical cancer; and prevention and screening. Ovarian cancer research included studies of various combinations of poly (ADP-ribose) polymerase inhibitors with chemotherapy, immune checkpoint inhibitors, and/or vascular endothelial growth factor inhibitors according to the clinical setting. For uterine corpus cancer, molecular classification upon which the decision of adjuvant treatments might be based, World Health Organization recommendation of 2-tier grading system (low grade vs. high grade), sentinel lymph node assessment and ovarian preservation in clinically early-stage endometrial cancer were reviewed. Molecular targeted agents including immune checkpoint inhibitors which showed promising anti-tumor activities in advanced/recurrent endometrial cancer were also included in this review.

中文翻译：

---

2020年妇科癌症主要临床研究进展

在2020年系列中，我们总结了妇科肿瘤学的主要临床研究进展，并提供了宫颈癌、卵巢癌和子宫体癌这三种妇科癌症中每一种最具影响力的研究的代表性数据。宫颈癌的审查涵盖靶向药物和免疫检查点抑制剂、早期宫颈癌根治性子宫切除术后的辅助放疗或同步/序贯放化疗、早期宫颈癌根治性手术；以及预防和筛查。卵巢癌研究包括根据临床情况对聚（ADP-核糖）聚合酶抑制剂与化疗、免疫检查点抑制剂和/或血管内皮生长因子抑制剂的各种组合进行研究。对于子宫体癌，辅助治疗决策可能依据的分子分类、世界卫生组织推荐的 2 级分级系统（低级别与高级别）、临床早期子宫内膜的前哨淋巴结评估和卵巢保留癌症进行了审查。本次综述还包括了包括免疫检查点抑制剂在内的分子靶向药物，这些药物在晚期/复发性子宫内膜癌中表现出有希望的抗肿瘤活性。